Why Cynata's GvHD Treatment Might Not Need a Phase Two Trial for FDA Approval, page-5

Save starting yet another thread, I don't know where else to put this.

Of course harassed by some of the denser and nastier posters of MSB, many CYP investors will understandably want little to do with MSB. But it has very marked context for CYP's ambitions, that MSB today set the GVHD "wholesale acquisition cost (WAC) of Ryoncil® is US$194,000 per intravenous infusion, irrespective of body weights." Most pundits calling it around $1.5 million per overall treatment.

Now I wonder if CYP might be able to undercut that price at still better margins than MSB, with cheaper, simpler, and superior scale and consistency manufacturing......?